Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity (Oncotarget (2014) 5 (1101-1110) DOI: 10.18632/oncotarget.1795);Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity

Oncotarget

Volumn 5, Issue 4, 2014, Pages 1101-1110

  Haagenson, Kelly K ^a,b   Zhang, Jessica Wei ^b   Xu, Zhengfan ^b   Shekhar, Malathy P V ^a,b   Wu, Gen Sheng ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; ERK; MKP 1; MKP 2; Tamoxifen sensitivity

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 2; STRESS ACTIVATED PROTEIN KINASE 1; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DUAL SPECIFICITY PHOSPHATASE; DUSP1 PROTEIN, HUMAN; DUSP4 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; ENZYMOLOGY; FEMALE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DUAL SPECIFICITY PHOSPHATASE 1; DUAL-SPECIFICITY PHOSPHATASES; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; TAMOXIFEN;

EID: 84897389897     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1795     Document Type: Erratum

References (28)

1. de Leeuw R, Neefjes J and Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. International journal of breast cancer. 2011; 2011:232435.
2. Musgrove EA and Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-643.
3. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005; 23(11):2469-2476.
4. Kurebayashi J. Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol. 2005; 56 Suppl 1:39-46.
5. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM and Webb P. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000; 74(5):311-317.
6. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev. 2007; 26(3-4):579-585.
7. Haagenson KK and Wu GS. Mitogen activated protein kinase phosphatases and cancer. Cancer biology&therapy. 2010; 9(5):337-340.
8. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 2008; 27(2):253-261.
9. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S, Coombes RC and Ali S. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocrine-related cancer. 2006; 13(3):851-861.
10. Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I and Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International journal of cancer Journal international du cancer. 2010; 126(2):545-562.
11. Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E and Auberger P. Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. Oncotarget. 2012; 3(12):1688-1699.
12. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G and Zhan F. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1(1):22-33.
13. Wang HY, Cheng Z and Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 2003; 191(2):229-237.
14. Sun H, Charles CH, Lau LF and Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993; 75(3):487-493.
15. Chu Y, Solski PA, Khosravi-Far R, Der CJ and Kelly K. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem. 1996; 271(11):6497-6501.
16. Franklin CC and Kraft AS. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem. 1997; 272(27):16917-16923.
17. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012; 3(9):954-987.
18. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. The Journal of clinical investigation. 1997; 99(7):1478-1483.
19. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE and Nicholson RI. Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinology. 2003; 144(3):1032-1044.
20. Haagenson KK and Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 2010; 29(1):143-149.
21. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M and Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68(3):826-833.
22. Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS and McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget. 2011; 2(7):538-550.
23. Peng DJ, Zhou JY and Wu GS. Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. Cell cycle (Georgetown, Tex). 2010; 9(23):4650-4655.
24. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Pinto JA, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature medicine. 2012; 18(7):1052-1059.
25. Shekhar MP, Gerard B, Pauley RJ, Williams BO and Tait L. Rad6B is a positive regulator of beta-catenin stabilization. Cancer Res. 2008; 68(6):1741-1750.
26. Shekhar MP, Santner S, Carolin KA and Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. The American journal of pathology. 2007; 170(5):1546-1560.
27. Zhou JY, Liu Y and Wu GS. The role of mitogen-activated protein kinase phosphatase-1 in oxidative damage-induced cell death. Cancer Res. 2006; 66(9):4888-4894.
28. Wang J, Zhou JY, Zhang L and Wu GS. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell cycle (Georgetown, Tex). 2009; 8(19):3191-3198.